Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiragolumab in R/R Multiple Myeloma and Non-Hodgkin Lymphoma
NCT04045028Phase 1Terminated
- Sponsor
- Genentech
- Start
- Jul 2019
- Primary completion
- Mar 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 2
01
Overview
Phase 1, open-label trial of tiragolumab in multiple myeloma (MM) and B-cell non-Hodgkin lymphoma (5 arms), sponsored by Genentech. Primary endpoint: Percentage of Participants With Adverse Events. Started Jul 2019; status: terminated.
02
Drugs
tiragolumab
03
Conditions
multiple myeloma (MM)B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT04045028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04045028.